November 2023 – Laprophan, a pioneering company in the pharmaceutical industry in Morocco, announces the acquisition of Amanys Pharma from SPE Capital and Proparco, subject to obtaining the required regulatory approvals.

In this context, Laprophan and Amanys Pharma aim to form a diversified pharmaceutical group in Morocco and Africa, built around specialized and complementary hubs.

Since the acquisition in 2020, SPE Capital and Proparco have supported the management of Amanys Pharma, with the main objectives being the sustained growth of the company, the expansion of its industrial capabilities, and the improvement of governance standards.

Laprophan will bring its industrial and R&D expertise to establish a new dynamic. Thanks to this merger, Laprophan and Amanys Pharma will be able to act in synergy to better meet the growing health needs in Morocco and across the continent.

Farid Bennis, Chairman and CEO of Laprophan, stated: “I am convinced that this merger between two pharmaceutical players with genuine synergies will better serve the interests of patients in Morocco and more broadly in Africa.”

Younous Elalamy, CEO of Amanys Pharma, said: “We are delighted with this partnership, which will ensure the continued development of our group while leveraging the various existing industrial and commercial complementarities between Amanys and Laprophan.”

Here are links to some articles published on this topic:

https://www.le1.ma/farid-bennis-rachete-lex-saham-pharma-de-moulay-hafid-elalamy/

https://medias24.com/2023/11/10/laprophan-acquiert-amanys-pharma/

https://ledesk.ma/encontinu/laprophan-annonce-lacquisition-damanys-pharma-de-spe-capital-et-proparco/

https://telquel.ma/instant-t/2023/11/01/laprophan-et-sinopharm-etendent-leur-partenariat-au-continent-african_1838891/

https://www.lavieeco.com/affaires/industrie-pharmaceutique-laprophan-soffre-amanys-pharma/